FTT 0.00% 0.5¢ factor therapeutics limited

If my take on it is correct the VenusIII results reflect those...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 86 Posts.
    lightbulb Created with Sketch. 9
    If my take on it is correct the VenusIII results reflect those expected from the placebo (SC).
    If that is incorrect disregard below!!
    VenusIII (n=49) .......................... VF00102 (n=113)
    week 12 ......... 41% fully healed ............................. ~50% fully healed

    week 4......... 25% wound reduction ....................... 50%wound reduction
    week 10........ 50% wound reduction ....................... 68% wound reduction
    week 12 ...... 55% wound reduction ........................ 70% wound reduction
    (Italics means measured from published curve Bioshares presentation)

    So the Venus III results, or very similar, would be expected to be embedded in the VF00102 interim results.

    Looking at week 12.......taking account of the fully healed to get stated average wound reduction values, the average wound reduction of those not fully healed would be 24% VIII and 40% VF.

    Looking quite nice to me so far.
    Last edited by saxman: 31/07/18
 
watchlist Created with Sketch. Add FTT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.